- Home
- MGNX vs CFFI Comparison
MGNX vs CFFI Comparison
Compare MGNX & CFFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- CFFI
- Stock Information
- Founded
- MGNX 2000
- CFFI 1927
- Country
- MGNX United States
- CFFI United States
- Employees
- MGNX N/A
- CFFI N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- CFFI Major Banks
- Sector
- MGNX Health Care
- CFFI Finance
- Exchange
- MGNX Nasdaq
- CFFI Nasdaq
- Market Cap
- MGNX 202.7M
- CFFI 228.1M
- IPO Year
- MGNX 2013
- CFFI 1998
- Fundamental
- Price
- MGNX $2.86
- CFFI $77.06
- Analyst Decision
- MGNX Hold
- CFFI
- Analyst Count
- MGNX 10
- CFFI 0
- Target Price
- MGNX $7.17
- CFFI N/A
- AVG Volume (30 Days)
- MGNX 642.4K
- CFFI 11.3K
- Earning Date
- MGNX 03-06-2025
- CFFI 01-28-2025
- Dividend Yield
- MGNX N/A
- CFFI 2.40%
- EPS Growth
- MGNX N/A
- CFFI N/A
- EPS
- MGNX N/A
- CFFI 6.04
- Revenue
- MGNX $141,329,000.00
- CFFI $114,063,000.00
- Revenue This Year
- MGNX $174.73
- CFFI N/A
- Revenue Next Year
- MGNX N/A
- CFFI N/A
- P/E Ratio
- MGNX N/A
- CFFI $12.44
- Revenue Growth
- MGNX 16.68
- CFFI N/A
- 52 Week Low
- MGNX $2.79
- CFFI $33.51
- 52 Week High
- MGNX $21.88
- CFFI $80.87
- Technical
- Relative Strength Index (RSI)
- MGNX 34.55
- CFFI 55.37
- Support Level
- MGNX $2.93
- CFFI $72.11
- Resistance Level
- MGNX $3.16
- CFFI $79.32
- Average True Range (ATR)
- MGNX 0.18
- CFFI 2.68
- MACD
- MGNX -0.02
- CFFI 0.44
- Stochastic Oscillator
- MGNX 1.90
- CFFI 63.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About CFFI C&F Financial Corporation
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum revenue from the Community Banking segment.